Esta publicación también está disponible en: English Español
Mexico’s Federal Commission for Protection Against Health Risks (Cofepris) may soon approve a vaccine to help combat the world-wide health threat of Mpox (formerly Monkey Pox).
Mexico does not have a specific vaccine or treatments aimed at combating the infection by the MPox virus. Disease management focuses primarily on relieving symptoms, caring for injuries and preventing complications.
It is currently reviewing a request from The Bavarian Nordic company for the marketing of the Jynneos vaccine. The vaccine is currently being administered in the USA for MPox. It requires two vaccinations, approximately four weeks apart.
The vaccine, which can be used for primary vaccination or revaccination, is indicated exclusively for adults 18 years of age and older with a high risk of exposure to the virus. It is not recommended for use in the general population, including children, pregnant or lactating women.
Mpox, known to cause painful skin rashes that usually appear on the face, palms and soles of the feet, is mainly transmitted from person to person through direct contact with skin lesions, scabs, contaminated body fluids or through respiratory droplets. Symptoms can begin five to 21 days after exposure and include headache, fever greater than or equal to 38o C, skin rash or lesions, back pain, growth or lymph node pain, and muscle pain.
It’s welcome news to the LGBTQ+ community in Mexico, which had petitioned Cofepris in August seeking the approval of a MPox vaccine in Mexico.
The petition was issued by the Mexican LGBTTTIQ+ Coalition, a group of organizations, activists, and human rights defenders in Mexico, committed to the health and well-being of the LGBTQ+ populations.
The petition “demand that the competent authorities act quickly and responsibly to protect public health against the threat of Mpox. The extraordinary call of the National Vaccination Council (CONAVA) and the prompt authorization of the vaccine by COFEPRIS are essential measures to address this health emergency and protect vulnerable populations in Mexico.”
A resolution is expected by mid-September.
Esta publicación también está disponible en: English Español
 may soon approve a vaccine to help combat the health threat.){kind=link}